Emir Festic1, Vikas Bansal2, Ognjen Gajic3, Augustine S Lee4. 1. Department of Critical Care, Mayo Clinic, Jacksonville, FL. Electronic address: festic.emir@mayo.edu. 2. Critical Care Research, Mayo Clinic, Jacksonville, FL. 3. Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN. 4. Department of Critical Care, Mayo Clinic, Jacksonville, FL.
Abstract
OBJECTIVE: To address clinical concern regarding the use of inhaled corticosteroids (ICSs) and the risk for pneumonia, particularly among patients with chronic obstructive pulmonary disease (COPD) and asthma. PATIENTS AND METHODS: A multicentered prospective cohort of patients admitted to the hospital from March 1, 2009, through August 31, 2009, with pneumonia or another risk factor for acute respiratory distress syndrome was analyzed to determine the risk for pneumonia requiring hospitalization among patients taking ICSs. The adjusted risk (odds ratio [OR]) for developing pneumonia because of ICSs was determined in a multiple logistic regression model. RESULTS: Of the 5584 patients in the cohort, 495 (9%) were taking ICSs and 1234 (22%) had pneumonia requiring hospitalization. In univariate analyses, pneumonia occurred in 222 (45%) of the patients on ICSs vs 1012 (20%) in those who were not (OR, 3.28; 95% CI, 2.71-3.96; P<.001). After adjusting in the logistic regression model, prehospital ICS use was not significantly associated with pneumonia in the whole cohort (OR, 1.20; 95% CI, 0.93-1.53; P=.162), among the subset of 589 patients with COPD (OR, 1.40; 95% CI, 0.95-2.09; P=.093), among the 440 patients with asthma (OR, 1.07; 95% CI, 0.61-1.87; P=.81), nor among the remaining 4629 patients without COPD or asthma (OR, 1.32; 95% CI, 0.88-1.97; P=.179). CONCLUSION: When adjusted for multiple confounding variables, ICS use was not substantially associated with an increased risk for pneumonia requiring admission in our cohort.
OBJECTIVE: To address clinical concern regarding the use of inhaled corticosteroids (ICSs) and the risk for pneumonia, particularly among patients with chronic obstructive pulmonary disease (COPD) and asthma. PATIENTS AND METHODS: A multicentered prospective cohort of patients admitted to the hospital from March 1, 2009, through August 31, 2009, with pneumonia or another risk factor for acute respiratory distress syndrome was analyzed to determine the risk for pneumonia requiring hospitalization among patients taking ICSs. The adjusted risk (odds ratio [OR]) for developing pneumonia because of ICSs was determined in a multiple logistic regression model. RESULTS: Of the 5584 patients in the cohort, 495 (9%) were taking ICSs and 1234 (22%) had pneumonia requiring hospitalization. In univariate analyses, pneumonia occurred in 222 (45%) of the patients on ICSs vs 1012 (20%) in those who were not (OR, 3.28; 95% CI, 2.71-3.96; P<.001). After adjusting in the logistic regression model, prehospital ICS use was not significantly associated with pneumonia in the whole cohort (OR, 1.20; 95% CI, 0.93-1.53; P=.162), among the subset of 589 patients with COPD (OR, 1.40; 95% CI, 0.95-2.09; P=.093), among the 440 patients with asthma (OR, 1.07; 95% CI, 0.61-1.87; P=.81), nor among the remaining 4629 patients without COPD or asthma (OR, 1.32; 95% CI, 0.88-1.97; P=.179). CONCLUSION: When adjusted for multiple confounding variables, ICS use was not substantially associated with an increased risk for pneumonia requiring admission in our cohort.
Authors: H Whitford; B Orsida; T Kotsimbos; M Pais; C Ward; L Zheng; T Williams; E H Walters; G Snell Journal: Ann Transplant Date: 2000 Impact factor: 1.530
Authors: M S Niederman; L A Mandell; A Anzueto; J B Bass; W A Broughton; G D Campbell; N Dean; T File; M J Fine; P A Gross; F Martinez; T J Marrie; J F Plouffe; J Ramirez; G A Sarosi; A Torres; R Wilson; V L Yu Journal: Am J Respir Crit Care Med Date: 2001-06 Impact factor: 21.405
Authors: Robert J F Laheij; Miriam C J M Sturkenboom; Robert-Jan Hassing; Jeanne Dieleman; Bruno H C Stricker; Jan B M J Jansen Journal: JAMA Date: 2004-10-27 Impact factor: 56.272
Authors: C P C de Jager; P C Wever; E F A Gemen; M G H van Oijen; A B van Gageldonk-Lafeber; P D Siersema; G C M Kusters; R J F Laheij Journal: Aliment Pharmacol Ther Date: 2012-10-03 Impact factor: 8.171
Authors: Valerie R Stolberg; Alexandra L McCubbrey; Christine M Freeman; Jeanette P Brown; Sean W Crudgington; Sophina H Taitano; Bridget L Saxton; Peter Mancuso; Jeffrey L Curtis Journal: J Immunol Date: 2015-05-18 Impact factor: 5.422
Authors: Joseph E Levitt; Emir Festic; Manisha Desai; Haley Hedlin; Kenneth W Mahaffey; Angela J Rogers; Ognjen Gajic; Michael A Matthay Journal: Ann Am Thorac Soc Date: 2021-04